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ARTICLE OPEN
Vaccine-induced, but not natural immunity, against the
Streptococcal inhibitor of complement protects against
invasive disease
Lionel K. K. Tan 1, Mark Reglinski1,5, Daryl Teo1, Nada Reza1, Lucy E. M. Lamb1,2, Vaitehi Nageshwaran1, Claire E. Turner1,6,
Mats Wikstrom3,7, Inga-Maria Frick4, Lars Bjorck4 and Shiranee Sriskandan 1✉
Highly pathogenic emm1 Streptococcus pyogenes strains secrete the multidomain Streptococcal inhibitor of complement (SIC) that
binds and inactivates components of the innate immune response. We aimed to determine if naturally occurring or vaccine-
induced antibodies to SIC are protective against invasive S. pyogenes infection. Immunisation with full-length SIC protected mice
against systemic bacterial dissemination following intranasal or intramuscular infection with emm1 S. pyogenes. Vaccine-induced
rabbit anti-SIC antibodies, but not naturally occurring human anti-SIC antibodies, enhanced bacterial clearance in an ex vivo whole-
blood assay. SIC vaccination of both mice and rabbits resulted in antibody recognition of all domains of SIC, whereas naturally
occurring human anti-SIC antibodies recognised the proline-rich region of SIC only. We, therefore, propose a model whereby
natural infection with S. pyogenes generates non-protective antibodies against the proline-rich region of SIC, while vaccination with
full-length SIC permits the development of protective antibodies against all SIC domains.
npj Vaccines            (2021) 6:62 ; https://doi.org/10.1038/s41541-021-00326-3
INTRODUCTION
Invasive disease caused by the human-specific pathogen,
Streptococcus pyogenes, also known as group A Streptococcus
(GAS), has been increasing since the 1980s and is associated with
mortality of ~20%1,2. Strains expressing the M1 protein, encoded
by emm1, are overrepresented amongst invasive isolates, and
account for over 30% of cases of necrotising fasciitis and
streptococcal toxic shock syndrome3. The Streptococcal inhibitor
of complement (SIC) is an extracellular protein, almost uniquely
expressed by emm1 S. pyogenes, and is one of several virulence
factors implicated in the propensity for emm1 isolates to cause
severe infection4.
Three distinct regions of SIC have been described: an N-
proximal short-repeat region, a central long- repeat region and a
C-proximal proline-rich region4,5. SIC binds to the C5b67 complex
of complement to inhibit the formation of the membrane attack
complex4,6, although the physiological role of this remains to be
determined. SIC also inhibits the function of host antimicrobial
factors, including lysozyme, alpha- and beta-defensins, secretory
leukocyte protease inhibitor, LL-37 and histones, and additionally
has a role in bacterial adherence to epithelial cells5,7–10. While
transcriptomic and mutagenesis studies have suggested a role for
SIC in invasive disease in vivo11,12, expression of SIC has not been
directly linked to the invasiveness of S. pyogenes in the clinical
setting. Recently, SIC was one of the 15 streptococcal proteins
detected in pleural fluid from a child with empyema caused by
emm1 S. pyogenes, indicating that SIC is expressed at high levels
during natural infection although it may be degraded13.
Despite a relatively low incidence of anti-M1 antibody, antibody
to SIC is found frequently (~40%) among humans from diverse
populations, including healthy people and also those with
previous streptococcal disease14–16. SIC is genetically highly
variable with over 300 sic alleles described and it is speculated
that human antibody at mucosal surfaces may drive SIC
variation17; however, the role of anti-SIC antibodies in host
immunity remains unclear. We set out to measure SIC production
by S. pyogenes in vitro and in vivo, and then determine whether
immunity to SIC can be protective. We found that, despite the
prevalence of naturally occurring anti-SIC antibodies in humans,
these antibodies do not confer opsonophagocytic protection
against S. pyogenes. In contrast, vaccine-induced antibodies
against full-length SIC do promote killing of S. pyogenes in a
whole-blood assay and, furthermore, provide protection against
experimental invasive streptococcal disease.
RESULTS
Expression of SIC in vitro among invasive and non-invasive
isolates
SIC expression in broth was quantified by western blot and
densitometry from 101 clinical isolates of emm1 S. pyogenes to
determine whether SIC expression was associated with the site of
bacterial isolate or original disease phenotype (Fig. 1). SIC
expression varied from 4.14 to 434.67 ng/ml (median 83.68 ng/
ml, IQR 45.43–126.63) in the culture supernatant. Although there
was a wide range of expression, there was no significant
difference in the detected levels of SIC expression between
invasive disease isolates (median 80.58 ng/ml, IQR 43.92–118.4),
and non-invasive isolates (median 88.06 ng/ml, IQR 42.69–150.7)
(Fig. 1a). Further categorisation of the 87 strains for which the site
of isolation was known did not reveal any association between SIC
expression and any specific disease aetiology (Fig. 1b). Among a
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subset of 39 isolates for which the sequence of the negative
regulatory locus covRS was known, SIC secretion in vitro was
higher in the 6 strains with covRS mutations (median 311.8 ng/ml)
than strains without mutations (median 88.06 ng/ml, P= 0.0017).
To quantify SIC expression in vivo, FVB/n mice were infected
intramuscularly with 5 × 107 CFU of S. pyogenes emm1 strain AP1
or SIC-negative derivative of AP19. SIC was detected in infected
muscle tissue extracts from AP1-infected mice (n= 5) 3 h post
infection (Fig. 1c); the median quantity of bacteria was 3.6 × 105
CFU (0.9–6.5 × 105 CFU) per mg of thigh tissue and the median SIC
level detected was 2.49 ng/mg of tissue (0.39–3.27 ng/ml of
tissue). The quantity of SIC detected did not appear to be related
to the number of bacteria recovered from the thigh tissue. SIC was
not detected in thigh tissue of mice infected with the SIC-negative
derivative (n= 3); the median quantity of bacteria was 6.6 × 105
CFU (6.5 × 105–1.47 × 106 CFU) of SIC-negative derivative per mg
of thigh tissue (Fig. 1c).
SIC is immunogenic in mice and immunisation improves
outcome following intranasal infection
Serum IgG directed against SIC is common in healthy human
populations14–16, but little is known about the protective role of
these antibodies against the disease. The potential protective role
of anti-SIC antibodies was therefore assessed in a mouse model of
infection. To determine whether recombinant SIC protein variant
SIC1.300 (rSIC1.300) was immunogenic, mice were immunised
with rSIC1.300 or sham vaccine containing PBS and adjuvant.
Following immunisation, anti-SIC antibodies could be detected in
a 1:64,000 dilution of immunised mouse sera (Fig. 2a). To assess
whether these titres translated into protective immunity, immu-
nised mice were infected with a contemporary emm1 S. pyogenes
strain H584 (a strain that expresses the SIC1.300 variant) via the
intranasal route using a volume known to reach the lung and
disseminate systemically. S. pyogenes lower respiratory tract
infection led to noticeable systemic disease manifested by clinical
features such as weight loss and change in posture. However,
mice immunised with recombinant SIC1.300 demonstrated
improved outcomes (time to humane endpoints) compared to
mice immunised with the sham vaccine (Fig. 2b), even when the
challenge dose was increased (Fig. 2c).
Immunisation with SIC protects against systemic bacterial
dissemination
To determine whether SIC immunisation provided protection
against systemic disease, in a separate experiment, SIC-immunised
mice were challenged intranasally and bacterial counts at the site
of infection and in distant tissues were quantified 48 h after
infection (Fig. 3). Bacterial counts recovered from the nose were
similar between both sets of animals, indicating that there were
no differences in dose or local bacterial replication between the
two groups (Fig. 3a). Compared to mice that received sham
vaccination, mice immunised with SIC1.300 had significantly
reduced bacterial counts in the spleen (Fig. 3b) and liver (Fig.
3c). Although 3/10 SIC-immunised mice were bacteraemic,
Fig. 1 Quantification of in vitro and in vivo SIC production. a, b The concentration of SIC in overnight culture supernatants from 101 emm1
S. pyogenes clinical isolates grouped by (a) invasive vs non-invasive disease phenotype or (b) site of isolation was quantified. Solid line
indicates median concentration of SIC from the group of isolates. Quantifications were performed by western blotting and densitometry
using a recombinant SIC (rSIC) standard ranging from 50 to 3.125 ng per well. c SIC was quantified in the thigh tissue of mice following a 3-h
intramuscular infection with the emm1 S. pyogenes isolate AP1 (five mice, lanes 1–5) or a SIC-negative AP1 derivative (three mice, lanes 6–8).
Quantifications were performed by western blotting and densitometry using a recombinant SIC (rSIC) standard ranging from 12.5 to 1.56 ng
per well.
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compared to 7/10 sham-immunised mice, there was no significant
difference in bacterial counts in the bloodstream (Fig. 3d).
A separate group of SIC-immunised and sham-immunised mice
were infected by the intramuscular route and bacterial counts
were assessed 24 h after infection. Again, while no differences in
bacterial load were observed at the site of inoculation in the
infected muscle, (Fig. 4a) a significant difference in the bacterial
counts in the spleen (Fig. 4b) and liver (Fig. 4c) was measured.
Very limited bacterial dissemination to the blood was observed
(Fig. 4d).
Vaccine-induced rabbit anti-SIC antibodies, but not naturally
occurring human antibodies enhance clearance of emm1 S.
pyogenes ex vivo
To assess the protective role of vaccine-induced immunity against
SIC ex vivo, polyclonal rabbit anti-SIC serum was generated using
recombinant SIC1:300. Cross-reactivity with other SIC variants and
native SIC from emm1 S. pyogenes culture supernatant was
confirmed by ELISA and western blotting (Supplementary Fig. 1).
To determine if vaccine-induced rabbit antibodies and/or naturally
occurring human antibodies to SIC could enhance clearance of
emm1 S. pyogenes in the ex vivo whole-blood assay, rabbit and
human anti-SIC antibodies were affinity-purified from rabbit
polyclonal serum and commercially available pooled human
immunoglobulin (ivIg), respectively. ELISA and western blot
analysis confirmed that anti-SIC antibody from both humans and
rabbits, that was affinity-purified using SIC1.300, was able to
detect full-length recombinant (r) SIC of three different variants
and also native SIC from emm1 S. pyogenes culture supernatant,
suggesting that immunogenicity was not restricted to a single SIC
variant (Supplementary Fig. 2).
Purified rabbit and human anti-SIC antibodies were added to
human whole blood from healthy individuals and growth of emm1
S. pyogenes was assessed over 3 h using a modified Lancefield
assay. Rabbit anti-SIC antibody reduced growth of the emm1
isolates H584 and AP1 compared to rabbit IgG isotype control
antibody (Fig. 5a). In contrast, human anti-SIC IgG did not inhibit
the growth of the emm1 isolate H584 in whole human blood,
compared to a control antibody (Fig. 5b). We further evaluated
naturally occurring SIC antibodies using a panel of human sera
previously determined to have high anti-SIC levels16. There was no
correlation between anti-SIC levels and bacterial growth inhibition
when heat-inactivated human serum from antenatal donors16 was
co-incubated with emm1 S. pyogenes growing in human whole
blood (Supplementary Fig. 3), further indicating that natural anti-
SIC antibodies in human serum do not promote opsonophago-
cytic killing of S. pyogenes. Together with the in vivo data from
mice, the findings indicated that immunisation of mice or rabbits
with SIC results in antibodies that have the potential to protect
against emm1 S. pyogenes infection. In contrast, naturally
occurring human anti-SIC antibodies lacked the protective activity
that was observed for vaccine-induced antibody.
Although SIC is a secreted protein, we considered the possibility
that SIC bound to the surface of the bacteria could be a target for
anti-SIC antibodies. However, using flow cytometry, we found no
evidence that murine anti-SIC had specific bacterial surface
binding activity when compared with sham-vaccinated mouse
serum. Furthermore, binding was considerably lower than the
positive control polyclonal Spy7 serum-targeted against seven
Fig. 2 SIC1.300 vaccination is immunogenic and induces a protective response against lower respiratory tract infection. a Serum was
obtained from mice on day 39 post immunisation with rSIC1.300 (open squares) or PBS (closed circles) and SIC1.300-specific IgG was
measured by ELISA. Data were obtained from ten mice per group, over three vaccination experiments. Mean and standard deviation are
shown. b, c FvB/n mice immunised with SIC1.300 (solid line) or sham-vaccinated (dashed line) were infected intranasally with (b) 2 × 107 CFU
(n= 15, pooled data from two independent experiments; one experiment of n= 5 SIC- immunised and n= 5 sham-immunised and one
experiment of n= 10 SIC-immunised and n= 10 sham-immunised) or (c) 2 × 108 CFU (n= 5 SIC-immunised and n= 5 sham-immunised) of the
emm1 S. pyogenes isolate H584 and culled when experimental endpoints were reached. Survival was compared using the log-rank test.
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known S. pyogenes surface antigens18 (Supplementary Fig. 4).
Similar results were obtained when purified rabbit anti-SIC and
rabbit isotype control antibody were compared (Supplementary
Fig. 4), suggesting that anti-SIC is unlikely to act via opsonisation,
consistent with findings that SIC is infrequently identified in S.
pyogenes cell wall preparations19.
Human, rabbit and mouse anti-SIC antibodies detect different
fragments of SIC
To determine the basis for the apparent difference between
natural human anti-SIC antibodies, and vaccine-induced rabbit or
mouse anti-SIC antibodies, the regions of SIC recognised by each
of the anti-SIC antibodies were studied using polypeptide
fragments of SIC (fragments 1, 2 and 3), which are based on SIC
from the emm1 S. pyogenes strain AP1 (Supplementary Fig. 5).
Whilst purified rabbit anti-SIC antibodies were able to recognise all
three SIC fragments by an ELISA-based assay, purified natural
human anti-SIC was able to detect only fragment 3, with limited
detection of fragment 1 or fragment 2 (Fig. 6a). Serum from mice
that had been immunised with full-length rSIC1.300 for the earlier
infection challenge experiments also detected all three SIC
fragments similar to findings in the rSIC1.300-immunised rabbit
serum (Fig. 6b). These findings were confirmed by western blot;
rabbit and mouse anti-SIC detected all three fragments, while
human anti-SIC detected only fragment 3 (Fig. 6c). Furthermore,
when the anti-SIC response was quantified from individual donor
human antenatal sera, the predominant response was against SIC
fragment 3 (Fig. 6d).
Immunisation with SIC fragments does not protect against
invasive disease
To ascertain whether immunity to any single SIC fragment would
be sufficient to induce protective immunity, mice were immunised
with recombinant SIC fragment 1, fragment 2, fragment 3 or a
sham vaccine containing PBS and adjuvant. Fragment 3 immuni-
sation was complicated by an unexpected hypersensitivity
reaction in 5/8 mice. Following immunisation, strong reactivity
was obtained against SIC fragments 1 and fragment 3, respec-
tively, with serum from mice immunised with the homologous SIC
fragment when analysed by ELISA (Fig. 7a) and western blotting
(Fig. 7b). No antibodies against SIC fragment 2 were detected by
either method.
Fig. 3 SIC1:300 vaccination prevents S. pyogenes dissemination
from a respiratory tract focus of infection. FvB/n mice immunised
with SIC1.300 (n= 10) or sham vaccine (n= 10) were infected i.n.
with 5 × 107 CFU of the emm1 S. pyogenes isolate H584. Mice were
culled 48 h post infection, and bacterial loads within the nose (a),
spleen (b), liver (c) and blood (d) were enumerated. For the nasal
tissue, bacterial enumeration was only performed on 6 mice per
group. Solid lines indicate the median CFU recovered from each
organ. *P < 0.05, one-tailed Mann–Whitney U test. ND not detected.
Fig. 4 SIC1:300 vaccination prevents S. pyogenes dissemination
from an intramuscular focus of infection. FvB/n mice immunised
with SIC1.300 (n= 5) or sham vaccine (n= 5) were infected I.M. with
5 × 107 CFU of the emm1 S. pyogenes isolate H584. Mice were culled
24 h post infection, and bacterial loads within the thigh muscle (a),
spleen (b), liver (c) and blood (d) were enumerated. Solid lines
indicate the median CFU recovered from each organ. *P < 0.05, one-
tailed Mann–Whitney U test. ND not detected.
L.K.K. Tan et al.
4
npj Vaccines (2021)    62 Published in partnership with the Sealy Institute for Vaccine Sciences
Mice immunised with individual SIC fragments were challenged
with 2 × 108 CFU of emm1 S. pyogenes AP1 by the intramuscular route
and the bacterial counts in the organs and at the site of infection
were quantified 24 h after infection. There was no significant
difference in dissemination to the bloodstream, liver, spleen or at
the site of infection between any of the groups (Fig. 7c). Thus, the
protection conferred against S. pyogenes by immunisation with full-
length rSIC could not be recapitulated by any single SIC domain.
Fig. 5 Rabbit but not human anti-SIC antibodies are protective in ex vivo whole-blood assay. a The emm1 S. pyogenes isolates H584 and
AP1 were grown in human whole blood with the addition of affinity-purified rabbit anti-SIC1.300 polyclonal antibodies (black bars) or rabbit
IgG isotype control antibodies (grey bars). Bacterial growth (multiplication factor) was determined after rotation at 37 °C for 3 h. Median and
range are shown for two separate experiments with three different donors. *P < 0.05 Wilcoxon matched-pair signed-rank test. b The emm1 S.
pyogenes isolate H584 was grown in human whole blood with the addition of purified human anti-SIC antibodies (black bars) or human
isotype control antibodies (grey bars). Bacterial growth (multiplication factor) was determined after rotation at 37 °C for 3 h. Median and range
are shown for five separate experiments with three different donors (IVIG and human anti-SIC antibodies) or four separate experiments with
two different donors (human isotype control antibodies). *P < 0.05 Wilcoxon matched-pair signed-rank test.
Fig. 6 Rabbit and mouse but not human anti-SIC antibodies recognise all three SIC fragments. a, b Immobilised recombinant SIC
fragments 1, 2 and 3 were incubated with (a) 0.1 mg/ml of affinity-purified human anti-SIC or rabbit anti-SIC1.300 antibodies, or (b) a 1:100
dilution of pooled serum from mice immunised with full-length SIC1.300. Median and range shown of ELISAs repeated at least twice. c Equal
quantities of recombinant SIC fragments 1, 2 and 3 were visualised by western blotting using 0.1 mg/ml of human anti-SIC or rabbit anti-SIC
antibodies, or a 1:250 dilution pooled serum from mice immunised with full-length SIC1.300. d Immobilised recombinant SIC fragments 1, 2
and 3 were incubated with a 1:100 dilution of heat-inactivated sera from individual antenatal donors, in which anti-SIC1.300 titres had been
determined previously. Data points represent mean A492 readings from two independent experiments and solid lines indicate the median.
L.K.K. Tan et al.
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DISCUSSION
Antibodies against SIC are widespread in populations world-
wide14–16, although the role that these antibodies play in
protection against infection with S. pyogenes remains unclear. In
this study, we have demonstrated that SIC is expressed
ubiquitously by invasive and non-invasive emm1 bacterial strains
in vitro and we have quantified SIC production in vivo.
Immunisation of animals with full-length SIC provided protection
against systemic bacterial dissemination. In contrast to vaccine-
induced immunity, natural human immunity to SIC is directed
against only one domain of SIC, and this is insufficient to confer
immunity.
Multiple functions have been attributed to SIC, which all appear
to aid bacterial evasion of host innate immunity6,8,9. The
upregulation of sic by invasive emm1 isolates that had undergone
a mutation in the bacterial two-component regulator covRS11
suggested that SIC may contribute to S. pyogenes invasiveness as
part of the covRS regulon. Whilst previous studies have examined
the role of the variation in sequence and size of SIC17,20–23, we
instead hypothesised that variation in SIC expression levels would
reflect the invasive phenotype of a strain. SIC expression by single
bacterial isolates has been quantified in two separate reports8,9;
however, to our knowledge, this is the first report to examine SIC
expression in a wider collection of invasive and non-invasive
emm1 S. pyogenes clinical isolates. Although SIC expression levels
varied widely, levels were not overall significantly higher amongst
invasive isolates. Of note, invasive isolates represented almost
two-thirds of the strains investigated and it is likely that only some
have mutations in covRS. Among a subset of isolates for which
covRS sequencing was undertaken, we did however observe
significantly heightened expression of SIC. We have, for the first
time, also demonstrated that SIC is detectable in infected murine
thigh tissue, which was the site of infection, in infected animals.
We attempted to detect SIC in muscle from a patient with
necrotising myositis caused by emm1 S. pyogenes; however,
samples were obtained after treatment with intravenous immu-
noglobulin, and showed too much cross-reactivity with reagents
used, precluding detection of SIC (data not shown). Recently, SIC
was one of just 15 S. pyogenes proteins detected in pleural fluid
from a child with empyema caused by emm1 S. pyogenes13,
underlining the potential for virulence factors such as SIC to be
upregulated during in vivo infection.
Antibodies against SIC are widespread and persistent amongst
human populations in geographically distinct regions14–16.
Despite the marked polymorphism of SIC, allele-specific responses
appear uncommon when serum is tested16. Intriguingly, anti-SIC
antibodies are identified more frequently than antibodies to M1
protein14. We set out to assess whether immunisation with one SIC
variant (SIC1.300) would be protective in vivo in two mouse
models of infection. rSIC-immunised mice had increased survival
compared to sham-immunised mice following respiratory tract
infection. Whilst there was no difference in bacterial counts in the
nasal tissue and lungs, immunity to SIC appeared to impact
bacterial dissemination beyond the site of infection; the observa-
tion that rSIC immunisation also reduced bacterial dissemination
from intramuscular infection provided further evidence to
support this.
The ability of antibodies raised against full-length SIC to
enhance clearance of S. pyogenes in whole blood and in the
mouse models potentially indicates a role in the inhibitory activity
of SIC function rather than any opsonic activity since we found
little convincing evidence of surface-localised SIC. The data are
consistent with previous work demonstrating the role of SIC
in vivo: SIC enhanced virulence in both intraperitoneal12 and
subcutaneous mouse models of S. pyogenes infection9,24. By
immunising mice with SIC and demonstrating reduced bacterial
dissemination following infectious challenge, our data suggest an
important role for SIC in emm1 S. pyogenes pathogenesis and,
based on observations in the whole-blood model, a potential role
in resistance to opsonophagocytic killing.
Fig. 7 SIC fragments are variably immunogenic and non-protective. a Sera were obtained from individual mice (n= 8 in each group)
immunised with recombinant SIC fragments 1, 2 or 3 and SIC fragment-specific IgG was measured by ELISA. Data points represent mean A492
readings from individual mice obtained in two independent experiments, and solid lines indicate the median. b Equal quantities of
recombinant SIC fragments 1, 2 and 3 were transferred to a membrane and incubated in 1:100 dilution of mouse anti-SIC fragment 1, 2 or 3
antiserum. c FvB/n mice immunised with SIC fragment 1, fragment 2 or sham vaccine (n= 8 in each group) were injected intramuscularly with
2 × 108 CFU of the emm1 S. pyogenes isolate. Mice were culled 24 h post infection and bacterial loads within the thigh muscle spleen, liver and
blood were enumerated. Data are displayed as CFU/10 mg of tissue (thigh, spleen and liver) or CFU/ml (blood) (median and range).
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Whilst human anti-SIC antibodies are abundant in populations,
our data suggest that these antibodies are not protective. One
possible explanation for this is that following immunisation with
full-length SIC, protective antibodies are raised to epitopes
throughout the mature SIC protein; however, following natural
infection, antibodies are only generated against epitopes within
fragment 3 of SIC. A previous study using sera from 29 individuals,
identified ten linear epitopes in SIC1.01 that were identified by
≥50% of the human anti-SIC sera. These epitopes were at sites in
SIC in which polymorphisms commonly occur, and were evenly
distributed within the equivalent of SIC fragments 1, 2 and 314.
When this was further analysed by phage display using two sera to
detect natively folded SIC peptides, 7/8 peptides recognised by
one serum and 11/12 peptides recognised by the other serum
spanned regions present in the equivalent of SIC fragment 3 (from
residue 167 onwards). Our data using ELISA and western blot
confirm that epitopes within fragment 3 are the most readily
recognised by human anti-SIC that had been purified from ivIg
pooled from over 1000 donors25.
The reasons that human anti-SIC antibody responses are
directed to a single domain only are unclear. One possibility is
that anti-SIC responses represent cross-reactive responses to
another, unrelated antigen, that has structural similarity to
fragment 3. Notably, SIC readily undergoes proteolysis by human
proteases such as human neutrophil elastase and bacterial
proteases such as SpeB14,26. The digestion of SIC by unknown
bacterial or host factors within human saliva27 provides an
alternative mechanism by which SIC fragments, rather than full-
length SIC, might be presented to the immune system.
The lack of protection following immunisation with separate SIC
fragments was surprising, especially considering that several
immune inhibitory functions of SIC have been localised to the
SRR and LRR contained within SIC fragments 1 and 2, respec-
tively5. Indeed, immunisation with SIC fragment 2 elicited minimal
antibody response, despite epitopes in this fragment being
detected with antibodies raised against full-length SIC, and also
human anti-SIC serum in a previous study14, suggesting that this
fragment may form part of a discontinuous epitope. Data
generated using various biophysical methods indicate that SIC
contains low levels of regular secondary and tertiary structures
(unpublished data); this could mean that discontinuous epitopes
form long-range contacts resulting in either stable or dynamic
tertiary structure assemblies. Resolution of the complete folded
structure of SIC would provide a better understanding of the
nature of these epitopes. Interestingly, few immune inhibitory
functions of SIC have been localised to the PRR of SIC contained
within fragment 3. Thus, an alternative explanation to the varying
immunogenicity of SIC domains is that, in humans, SIC fragments
1 and 2 bind to host ligands concealing these regions from the
host, whilst epitopes in SIC fragment 3 are abundantly available.
Whilst SIC binds to both human LL-37 and mouse cathelicidin12,
previous studies assessing other ligands of SIC have used only
human proteins5,8,9,24,26. It remains unclear whether SIC binds to
other mouse proteins and hence the lack of immunogenicity of
fragment 2 compared to fragment 1 may be due to differential
binding to mouse proteins.
At first glance, a vaccine based on a polymorphic antigen found
in only one serotype does not seem an attractive proposition.
However, in light of difficulties in developing an effective S.
pyogenes vaccine over the last 70 years, and the dominance of the
emm1 lineage, alternative approaches must be considered. The
successful introduction of multicomponent vaccines for other
bacterial infections indicates that the inclusion of multiple novel
antigens in a vaccine may be important. In addition, antibodies
directed against single-virulence factors are being developed as
adjunctive therapy for a number of serious diseases caused by
other bacteria. Our data suggest that the inclusion of SIC in a
multicomponent vaccine could have the potential to reduce the
burden of disease caused by highly invasive emm1 S. pyogenes
and goes some way to explain the anomaly of widespread anti-SIC
immunoreactivity in an otherwise susceptible population.
MATERIALS AND METHODS
Bacterial strains
S. pyogenes emm1 strain H584 was isolated from a case of lethal
postpartum sepsis16. An additional 100 emm1 clinical S. pyogenes isolates
from the 1930s through to 2013 were referred to Imperial College from
diagnostic laboratories, linked to available clinical data and anonymised as
approved by the local research ethics committee (06/Q0406/20). In total,
68 isolates were from invasive disease and 32 were from non-invasive
disease. Specific disease aetiologies were not known for 13 isolates. S.
pyogenes isolates were identified as emm1 via sequencing of the emm
gene, which encodes the M protein (https://www2a.cdc.gov/ncidod/
biotech/strepblast.asp). Invasive disease-associated isolates were defined
as S. pyogenes isolated from a normally sterile site or a non-sterile site with
a clinical diagnosis of necrotising fasciitis or septic shock. Non-invasive
disease-associated isolates were defined as S. pyogenes isolated from non-
sterile sites with no clinical signs indicating severe/invasive disease. S.
pyogenes emm1 strains AP1 and SIC, a mutant derivative not expressing
SIC, were used in experiments where a SIC-negative emm1 isolate was
required and had been described previously9.
All streptococcal strains were cultured on Columbia horse blood agar
(CBA) (E&O Laboratories Ltd, Bonnybridge, Scotland) or in Todd-Hewitt
broth (THB) (Oxoid, Basingstoke, UK) at 37 °C, 5% CO2 without shaking.
Escherichia coli were cultured in Luria-Bertani broth (Oxoid) with 100 μg/ml
ampicillin (Sigma-Aldrich, Dorset, UK).
Recombinant SIC proteins
Recombinant full-length SIC proteins were purified using affinity chroma-
tography with a His-bind column as per the manufacturer’s instructions
(Novagen, Merck, Darmstadt, Germany). sic1.300, from emm1 strain H584,
sic1.02 and sic1.301, used in initial validation experiments, were expressed
in E. coli using the pET19b expression vector (Novagen, Nottingham, UK),
as previously described16. Recombinant SIC fragment 1 (amino acids 1–69),
fragment 2 (amino acids 70–166) and fragment 3 (amino acids 167–273)
were based on the originally published sic sequence of the emm1 strain
AP14 and were expressed in E. coli, purified by nickel affinity chromato-
graphy, processed with TEV protease to remove the His tag, purified by
reverse-phase chromatography and lyophilised.
Murine immunisation and infection challenge
Female 6–8-week-old FVB/n mice (Charles River, Margate, UK) were
immunised intramuscularly with 30 μg of recombinant SIC protein or
recombinant SIC fragments 1, 2 and 3 emulsified 1:1 in Freund’s
incomplete adjuvant (Sigma-Aldrich) on days 0, 21 and 35; sera were
collected by tail bleed on days 39–41. A control group of mice were
immunised with phosphate-buffered saline (PBS) and adjuvant (sham
vaccination). On days 42–45, mice were infected with emm1 S. pyogenes
strain H584 after full-length SIC immunisation, or S. pyogenes strain AP1
following SIC fragment immunisation (as SIC fragments were derived from
SIC AP1). For respiratory tract infection, two invasive disease isolates were
used. Mice were briefly anaesthetised with isoflurane and 2 × 107 CFU or
2 × 108 CFU of S. pyogenes were administered by inhalation (5 μl of
bacterial suspension per nostril). Mice were monitored for seven days and
any mice reaching defined humane endpoints were euthanised. For
intramuscular infection, mice received 5 × 107 CFU of S. pyogenes directly
into the thigh muscle. In some experiments, mice were euthanised (after
48 h for intranasal infection and 24 h for intramuscular infection) and blood
and tissue (homogenised in PBS) were taken for culture.
Purification of antibodies from serum or human intravenous
immunoglobulin
Recombinant SIC conjugated to cyanogen bromide-activated agarose was
used to affinity purify anti-SIC antibodies from rabbit anti-SIC serum or
commercially available human pooled ivIg. Recombinant SIC1.300 (1mg/
ml) in coupling buffer (0.1 M sodium bicarbonate, 0.5 M sodium chloride,
pH 8.3) was applied to a chromatography column containing CnBr-
activated agarose (Sigma-Aldrich) at room temperature for 2 h. Following
washing with coupling buffer, 0.2 M glycine was applied at room
L.K.K. Tan et al.
7
Published in partnership with the Sealy Institute for Vaccine Sciences npj Vaccines (2021)    62 
temperature for 2 h. The SIC-CnBr resin was then washed extensively by
alternating between coupling buffer and 0.1 M acetate buffer containing
0.5 M sodium chloride, pH 4. The resin was equilibrated in Tris-buffered
saline 1 [(TBS1), 50 mM Tris, 150 mM NaCl, pH 7.5], then to purify anti-SIC
antibodies, either serum from a rabbit immunised with SIC1.300, or human
pooled ivIg (Privigen immune globulin, CSL Behring, PA, USA) was applied
to the SIC-CnBr resin. The resin was washed extensively with TBS1 and Tris-
buffered saline 2 [(TBS2), 20mM Tris, 2 M NaCl, pH 7.5]. Purified antibodies
against SIC were eluted in fractions from the resin using 0.2 M glycine-HCl,
pH 2.2 and neutralised with 1 M Tris-HCl, pH 8.0. Fractions containing
purified anti-SIC antibodies were pooled and dialysed into PBS overnight at
4 °C. Antibody concentrations were determined using the Coomassie-
Bradford assay. From 12ml of rabbit anti-SIC serum, ~2ml of purified
rabbit anti-SIC antibody (0.5 mg/ml) was obtained, and from 20ml of
human pooled ivIg, ~0.5 ml of purified human anti-SIC antibody (0.1 mg/
ml) was obtained.
Human whole-blood phagocytosis assay
Lancefield whole-blood assays were performed to assess the protective
effect of rabbit and human anti-SIC antibodies ex vivo. Modification of the
classical Lancefield assay28 was undertaken through the addition of
purified antibodies or serum to human whole blood. Approximately 50
CFU of emm1 S. pyogenes strain H584 or AP1 were inoculated into
heparinised human whole blood obtained from healthy donors as
described28. Mixtures of whole blood, bacteria and anti-SIC (or serum)
were incubated for 3 h at 37 °C with end-over-end rotation. Bacterial
survival was quantified as the multiplication factor of the number of
surviving colonies relative to the starting inoculum and tested in triplicate.
To assess the effect of rabbit anti-SIC, purified rabbit anti-SIC antibodies
were added to whole blood. Rabbit IgG isotype control antibody
(ab176094, Abcam, Cambridge, UK) was used as a control. For separate
studies with H584 using human anti-SIC, either serum from 79 healthy
antenatal patients or purified human anti-SIC from human pooled ivIg
were added to whole blood. Antenatal sera were previously used and
tested for anti-SIC1.300 antibody levels (measured as ivIg-equivalent anti-
SIC)16. A human IgG isotype control (Novus biological, CO, USA) was used
as a control.
ELISA-based assay
To assess the antibody response of immunised mice, 96-well polystyrene
plates (Nunc, ThermoScientific, MA, USA) were coated with 100 ng of full-
length SIC1.300 or SIC fragments 1, 2 or 3 overnight at 4 °C, washed and
blocked for an hour with 3% normal goat serum (Sigma-Aldrich) diluted in
PBS–0.1% Tween20 (PBST). Test sera were then added at a range of
dilutions. Binding was detected using HRP-conjugated goat anti-mouse
IgG (Abcam) and incubated for an hour at room temperature. The
substrate (ONPG, Sigma-Aldrich) was added to wells, the reaction was
stopped with 3N HCl and the OD A492 read with a μQuant spectro-
photometer (Biotek, VT, USA). To compare cross-detection of recombinant
SIC variants or SIC fragments by rabbit polyclonal anti-SIC1.300 serum or
purified SIC antibody, plates were coated with SIC1.02, SIC1.301 and
SIC1.300 or SIC fragments 1, 2 and 3 and binding was detected using 1 in
25,000 dilutions of HRP-conjugated goat anti-rabbit IgG (Life Technologies,
Paisley, UK). To determine detection of SIC fragments by human purified
anti-SIC antibody or antenatal serum, plates were coated with SIC1.300 or
SIC fragments 1, 2 and 3, and binding was detected using 1 in 25,000
dilution of HRP-conjugated goat anti-human IgG (Sigma-Aldrich).
SDS-PAGE and western blot
Protein samples were separated by sodium dodecyl sulfate polyacrylamide
gel electrophoresis (SDS-PAGE) using NUPAGE 10% Bis-Tris Gels (Life
Technologies), run in NUPAGE MES Running Buffer (Life Technologies).
Following SDS-PAGE, proteins were transferred onto PVDF membranes
(Amersham Hybond-LFP membranes (GE Healthcare, Buckinghamshire,
UK)), or nitrocellulose membranes (Amersham Protran, GE Healthcare)
using cold tris-glycine transfer buffer (0.025M Tris, 0.2 M glycine). For
quantification of SIC and cross-detection of SIC variants, following blocking
in PBST with 5% skimmed milk powder, SIC was detected by probing with
1 in 10,000 dilutions of rabbit polyclonal anti-SIC1.300 for 2 h at room
temperature. Proteins were visualised by incubation in 1 in 50,000 dilution
of HRP-conjugated goat anti-rabbit IgG (Life Technologies) for an hour
followed by Amersham ECL Prime Western Blotting Detection Reagent (GE
Healthcare) exposed to Amersham Hyperfilm ECL (GE Healthcare). For
cross-detection of SIC variants using purified human anti-SIC, membranes
were probed with 1 in 10,000 dilution of human anti-SIC followed by 1 in
50,000 dilution of HRP-conjugated goat anti-human IgG (Sigma-Aldrich). To
directly compare detection of SIC fragments by purified human and rabbit
anti-SIC antibodies, purified antibodies were first diluted to the same
concentration (0.1 mg/ml in PBS), then used at 1 in 1000 dilution to probe
membranes, followed by secondary antibodies as outlined. Finally, for
detection of SIC fragments by mouse anti-SIC fragments 1, 2 and 3, serum
from groups of mice immunised with each fragment was pooled and used
to probe membranes at 1 in 100 dilution, followed by 1 in 50,000 dilution
of HRP-conjugated goat anti-mouse IgG (Abcam). Full, unmodified western
blots for Figs. 1c, 6c and 7b are displayed in separate Supplementary
Materials (Supplementary Fig. 6). All western blots that use the same
reagents and that are presented in the same panel derive from the same
experiment and were processed in parallel.
Quantification of SIC expression in culture supernatant and
in vivo
S. pyogenes strains were grown overnight in THB at 37 °C with 5% CO2. No
specific adjustment was made for variation in growth for each strain, as
previous literature indicates that SIC expression reaches a plateau after 6 h
as bacteria reached the stationary phase9. Cultures were then centrifuged
at 2500×g for 10 min at 4 °C and proteins from the supernatant were
precipitated using 10% trichloroacetic acid (TCA) with acetone (Sigma-
Aldrich). In total, 1700 μl of TCA-acetone was added to 300 μl of culture
supernatant and incubated at −20 °C for an hour. Samples were washed
twice with ice-cold acetone and allowed to dry before being resuspended
in 30 μl of sample treatment buffer (lithium dodecyl sulfate sample buffer
(Life Technologies); 100 mM DL-dithiothreitol (Sigma-Aldrich)), heated at
70 °C for 10min and used for western blot analysis.
For in vivo determination of SIC, female 6–8-week-old FVB/n mice
(Charles River, Margate, UK) were infected intramuscularly with either 5 ×
107 CFU of emm1 S. pyogenes strains AP1 or SIC and culled 3 h after
infection. Infected thigh muscle was homogenised in PBS and centrifuged
at 16,000×g for 5 min. The supernatant was added to the sample treatment
buffer, heated at 70 °C for 10min and used for western blot analysis. Serial
dilutions of known quantities of SIC1.300 were included on each gel to
generate the standard curve, and densitometry was undertaken with
Image J software (National Institutes of Health, MD, USA) enabling pixel
values to be converted to concentrations.
Flow cytometry
To determine binding of murine and rabbit anti-SIC to S. pyogenes cell
surface, ~1 × 108 CFU S. pyogenes H584 cells were harvested from
overnight culture in THB and washed twice in PBS. Cells were then
incubated in a 1 in 10 dilution of serum in PBS from mice immunised with
SIC1.300, sham vaccine or (as a positive control) multicomponent Spy7
vaccine candidate18, or 1 in 100 dilution of purified rabbit anti-SIC antibody
(or pre-immune rabbit serum) for 30min at 37 °C. Cells were then washed
twice in PBS-Tween, before incubating with 50 µl of AlexaFluor 647-
labelled goat anti-mouse or FITC-labelled goat anti-rabbit IgG (Life
Technologies) diluted 1 in 200 in PBS, on ice. Flow cytometry was
performed on a FACSCalibur (Becton Dickinson, Oxfordshire, UK) counting
20,000 events. Data were analysed using FlowJo software (Tree Star Inc.).
Statistical analyses
Non-parametric tests were used for comparisons and were performed with
GraphPad Prism 6.0 software (GraphPad Software, CA, USA). Samples sizes
were selected based on pilot studies or previous studies29. No randomisa-
tion or blinding was performed.
Study approval
The analysis of anonymised samples and bacteria from patients with
suspected infection was approved by an NHS Research Ethics Committee
(REC reference 06/Q0406/20). Human blood cells from normal donors were
obtained following informed consent from a sub-collection of the Imperial
College Healthcare NHS Trust Tissue Bank.
All animal procedures were conducted in accordance with UK Home
Office guidance and approval. Procedures were approved by the
Institutional Imperial College London Animal Welfare Ethical Review Board
(AWERB) and authorised by a Home Office Project Licence (PPL70/7379).
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Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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